drugset

drugset / Trial / NCT00542022

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

NCT00542022 ↗

Phase 2 Completed 149 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate the clinical effectiveness of MK0812 in the treatment of Arthritis.

Timeline

Start: 2004-06
Primary completion: 2005-05
Completion: 2005-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK0812	Small molecule	—	—

Indications